Get the Stockscreener App
2.60
1.96%
0.05
After Hours:
2.50
-0.10
-3.85%
Aytu Biopharma Inc stock is traded at $2.60, with a volume of 143.13K.
It is up +1.96% in the last 24 hours and up +18.72% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
See More
Previous Close:
$2.55
Open:
$2.57
24h Volume:
143.13K
Relative Volume:
1.20
Market Cap:
$26.49M
Revenue:
$66.38M
Net Income/Loss:
$-14.18M
P/E Ratio:
-0.9261
EPS:
-2.8074
Net Cash Flow:
$-5.17M
1W Performance:
+2.77%
1M Performance:
+18.72%
6M Performance:
+19.27%
1Y Performance:
+52.94%
1-Day Range:
$2.51
$2.62
1-Week Range:
$2.4194
$2.62
52-Week Range:
$0.95
$2.82
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.60 | 25.98M | 66.38M | -14.18M | -5.17M | -2.8074 |
|
ZTS
Zoetis Inc
|
125.82 | 55.71B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.38B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.11 | 44.89B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.21 | 35.96B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
487.25 | 21.36B | 3.08B | 1.24B | 1.07B | 25.61 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Initiated | Lake Street | Buy |
| Jun-30-25 | Initiated | Ascendiant Capital Markets | Buy |
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Published on: 2025-12-24 03:59:28 - moha.gov.vn
Can Aytu BioPharma Inc. stock sustain revenue growthJuly 2025 Outlook & Capital Efficiency Focused Strategies - Улправда
Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st
How Aytu BioPharma Inc. (AY20) stock reacts to fiscal policiesJuly 2025 Macro Moves & Weekly Return Optimization Plans - Улправда
Is Aytu BioPharma Inc. stock attractive for income investors2025 Winners & Losers & Low Risk High Win Rate Picks - Улправда
Will Aytu BioPharma Inc. stock deliver shareholder valueTrade Performance Summary & Low Drawdown Trading Strategies - DonanımHaber
Why Aytu BioPharma Inc. stock is favored by top institutionsLayoff News & Stepwise Trade Execution Plans - DonanımHaber
Why Aytu BioPharma Inc. stock attracts high net worth investorsJuly 2025 Sentiment & Precise Swing Trade Alerts - DonanımHaber
How sustainable is Aytu BioPharma Inc. stock dividend payoutEarnings Growth Summary & Safe Capital Allocation Plans - DonanımHaber
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City - ACCESS Newswire
Depression drug EXXUA takes center stage at New York investor event - Stock Titan
Aytu BioPharma launches depression drug EXXUA in U.S. market - Investing.com India
Aytu BioPharma launches depression drug EXXUA in U.S. market By Investing.com - Investing.com Nigeria
Aytu BioPharma stock rises after commercial launch of depression drug EXXUA - Investing.com Canada
Aytu BioPharma (AYTU) Launches EXXUA for Major Depressive Disorder in U.S. - GuruFocus
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults - Times Argus
Aytu BioPharma (Nasdaq: AYTU) makes EXXUA depression drug commercially available in US - Stock Titan
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome - ACCESS Newswire
AWM Investment Company Inc. Takes $1.35 Million Position in Aytu BioPharma Inc. $AYTU - Defense World
Aytu BioPharma (NASDAQ:AYTU) Given New $13.00 Price Target at Ascendiant Capital Markets - Defense World
Aytu BioScience Stockholders Approve Key Proposals - TipRanks
AYTU FinancialsIncome Statement - Quiver Quantitative
Ascendiant Capital Maintains Aytu BioPharma (AYTU) Buy Recommendation - Nasdaq
Ascendiant Capital raises Aytu Biosciences stock price target on Q1 beat - Investing.com Canada
AYTU Analyst Rating Update: Ascendiant Capital Raises Price Targ - GuruFocus
Revenue per share of Aytu BioPharma, Inc. – LSX:A3D38R - TradingView — Track All Markets
Will Aytu BioPharma Inc stock outperform Nasdaq index2025 Price Targets & Risk Controlled Daily Trade Plans - BỘ NỘI VỤ
How Low Can Aytu BioPharma Stock Really Go? - Trefis
Will Aytu BioPharma Inc. (AY20) stock profit from AI boom2025 Analyst Calls & Safe Entry Point Alerts - Newser
Will Aytu BioPharma Inc. (AY20) stock profit from fiscal stimulusJuly 2025 Patterns & Stock Portfolio Risk Management - Newser
How Aytu BioPharma Inc. (AY20) stock moves in volatile trading sessionsMarket Risk Report & Verified Technical Trade Signals - Newser
Is Aytu BioPharma Inc. (AY20) stock a fit for income portfoliosJuly 2025 Sector Moves & Fast Entry and Exit Trade Plans - Newser
Is Aytu BioPharma Inc. (AY20) stock resilient in recession scenariosJuly 2025 Catalysts & Growth Focused Entry Point Reports - Newser
Aytu BioPharma (NASDAQ:AYTU) Upgraded at Zacks Research - Defense World
Aytu BioPharma outlines $10M EXXUA launch investment and targets breakeven at $17.3M quarterly revenue as ADHD franchise holds strong - MSN
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference - ACCESS Newswire
Aytu BioPharma (NASDAQ: AYTU) to Showcase at NobleCon21, Dec. 3 Presentation Webcast - Stock Titan
Aytu BioPharma Inc AY20 Stock Analysis and ForecastFundamental Strength Indicators & Superior Trading Strategies - earlytimes.in
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates - MSN
Positive Signs As Multiple Insiders Buy Aytu BioPharma Stock - Yahoo Finance
Published on: 2025-11-21 03:45:24 - newser.com
Why Aytu BioPharma Inc. (AY20) stock is trending on social mediaOil Prices & Real-Time Stock Entry Alerts - newser.com
Published on: 2025-11-20 04:27:18 - newser.com
Is Aytu BioPharma Inc. stock cheap at current valuationJuly 2025 Selloffs & AI Driven Price Predictions - newser.com
What risks investors should watch in Aytu BioPharma Inc. stockPortfolio Risk Summary & Reliable Entry Point Trade Alerts - newser.com
Pre Market Movers: NUTX, AYTU, NOTV Swing Big - RTTNews
What MACD signals say about Aytu BioPharma Inc.July 2025 Update & Low Drawdown Trading Techniques - newser.com
Why Aytu BioPharma Inc. stock remains resilientJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Regression analysis insights on Aytu BioPharma Inc. performance2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aytu Biopharma Inc Stock (AYTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Disbrow Joshua R. | Chief Executive Officer |
Jun 09 '25 |
Buy |
1.50 |
66,666 |
99,999 |
153,257 |
| Disbrow Joshua R. | Chief Executive Officer |
Feb 28 '25 |
Buy |
1.30 |
15,000 |
19,500 |
86,591 |
8.30%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):